Company Overview and News
Chicago, IL – August 13, 2018 – Zacks Equity Research highlights Buckle (BKE - Free Report) as the Bull of the Day, Cars.com(CARS - Free Report) asthe Bear of the Day.
FOX BKE CARS FOXA
The automotive industry is facing some headwinds right now. Rising interest rates certainly don’t help when consumers are out there looking for their next purchase. It can have buyers thinking about staying in their existing cars longer. There is a also a huge supply of used cars flooding the market and putting pressure on used car prices. That’s making used cars that much more attractive and forcing manufacturers to give huge incentives on new leases.
EXPE WYNN UCTI CARS UCTT
Good morning, and welcome to the Cars.com 2018 Second Quarter Earnings Conference Call. Hosting the call this morning are Alex Vetter, President and Chief Executive Officer; and Becky Sheehan, Chief Financial Officer. This call is being recorded, and a live webcast can be found at investor.cars.com. A replay of the webcast will be available at this website until August 23, 2018.
Cars.com (CARS - Free Report) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.70 per share a year ago. These figures are adjusted for non-recurring items.
cars-8k_20180808.htm UNITED STATES
2018-08-04 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SYY AMAL RUTH BECN QES WHR HABT VIAB STI-A TSN WING SNAP MRCY WHD JCOM NWSA GPRE CRSP MDT REV GPK ZOES VCTR MGM WSO DFRG CTB OLED RAD GMVHF TEN HMI FLBD AGN CL AAPL UCBI KO USAP CBS GJV RRGB MUSA MCHP DDD "QES" VC TSLA CAKE APTV VPG BYD ARHVF EAT XON AMRS BLMN LDOS CVS UAL AMZN AIT NDSN CABO UPS KDP AAL CARS BR STE MAR REVG STI CLX BKEP TXRH DAN PG YELP TREC CDLX STMP ANDV MAR.WI MYL TSNU NWS KWR GM DIN FRPT DIS ECL F M FDX K BMI TGT ZG BKNG EOLS THRM DPZ ORLY
Cars.com Inc. (CARS - Free Report) was a big mover last session, as the company saw its shares rise 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $28.25 to $30.42 in the past one-month time frame.
2018-07-09 investorplace - 1
Spinoff stocks long have been a group targeted by value investors. Well-known investor Joel Greenblatt is among those who look for value, particularly soon after the spin is complete.
NC GOOG WMT GTN.A AAI AMZN IDT.WI RFL.WI AA IDT IDT ARNC LOGI CARS TGNA GTN HBB GOOGL RFL VZ STRP NTGR
Chicago, IL – June 6, 2018 – Zacks Equity Research highlights Tesla (TSLA - Free Report) as the Bull of the Day, Cars.com (CARS - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Ambarella, Inc. (AMBA - Free Report) .
LOPE NWDVW WDC NYTAB AMBA CARS FITBI CFIN CFG XEL DQ CIWV SCVL ARW FITB NEWM LAD
Cars.com Inc. (CARS - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for CARS broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
2018-05-18 sec.gov - 1
cars-8k_20180518.htm UNITED STATES
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CARS / Cars.com Inc on message board site Silicon Investor.
as of ET